**REVIEW ARTICLE ON NUCLEAR MEDICINE**

**Ms. Harsha. K. Donde1, Ms. Archana. D. Kahar2 and Dr. Sachin B. Somwanshi3**

1. Research Scholar, Department of Pharmaceutics, PRES’s, College of Pharmacy (For Women), Chincholi, Nashik, MH,India-422102.

E-mail:dondeharsha@gmail.com

1. Research Scholar, Department of Pharmaceutics, PRES’s, College of Pharmacy (For Women), Chincholi, Nashik, MH, India-422102.

E-mail:archanakatte2018@gmail.com

1. Associate Professor, Department of Pharmaceutics, P.R.ES’s, College of Pharmacy (For Women), Chincholi, Nashik, MH, India-422102.

E-mail:sachinsomwanshi27@gmail.com

**Abstract:**

Over the course of decades, the field of nuclear medicine (NM) has undergone both progressive and dramatic developments, owing primarily to responsive and flexible shifts in the global manufacturing and utilization of radiation therapies (RPh), as well as the development of new technology. Imaging devices capable of characterizing pictures, such as single-photon emission computed tomography/computed tomography [CT], positron emission scanning [PET]/CT, and PET/magnetic response. Naturally, as the NMRPh progresses, many critical lessons are acquired along the road. To ensure effective communication with the referral medical community and health services officials, it is felt necessary for the NM-RPh belonging to have a list(s) of indications for NM, classified on the basis of value levels, at the NM coarse level as well as medical specialty-wise, and related value levels..

**Keyword**: Radiopharmaceuticals, PET-CT, single-photon emission computed tomographic value matrix, clinical developments..

**Introduction**

The radiotracer concept, which underlies the use of radionuclides and radiopharmaceuticals to study the body, was originally explained by George de Hevesy, recognized as the "father of nuclear medicine" stability of atoms and molecules. According to the "tracer principle," "radiopharmaceuticals" can be used to explore the system and take part in biological processes in very small doses without changing or disturbing them[1]. The use of radiopharmaceuticals (RPh) is crucial to every procedure in the area of nuclear medicine (NM), making it distinctive. A carrier molecule that provides biospecificity for the organ, lesion, or dysfunction being treated is blended with a radioisotope (radioisotopes [RI]) generated in a research reactor (RR) or particle accelerator (such as a medical cyclotron [MC]) to transmit radiation used for detection-based imaging or for personalized treatment. RPh consists of a radioactive substance that offers radiation for detection-based imaging or for targeted therapy and a delivery molecule that offers biospecificity for the organ, tumor, or disorder receiving therapy (radioisotopes [RI], produced in a research reactor [RR] or particle accelerator like a medical cyclotron [MC][2]. In nuclear medicine, therapies include either locoregional therapies, such as locally injected microspheres to treat liver cancer, or selectively interacting radioactive materials (substances that target specific antigens or receptors), such as radioiodine. A ranking of the most significant and well-known treatments that have been given the green light for marketing [3].

**Developmental Advances and Milestones Radiopharmaceuticals**

After the extensive use of 131I for both evaluation and treatment, a considerable rise was first provided by 99mTc-based imaging agents in NM during the 1980s and 1990s (planar initially and SPECT subsequently), and then by PET trace elements, including 18F, also known (since 2000). The development of RPh progressed along a route that has become progressively sound, from chemistry-basonger. by using better targeted techniques and carefully finding the proper biochemically derived moieties linked to a particular lesion or clinically relevant malfunction. The development and introduction of several radiopharmaceuticals (RPh), particularly in three key ametastasis

The following significant clinical achievements might be mentioned: innovations to multidisciplinary initiatives, and has become even strhas progressed along a route that has become progressively sound, from chemistry-based innovations to multidisciplinary initiatives, and has become even stronger. by using better targeted techniques and carefully finding the proper biochemically derived moieties linked to a particular lesion or clinically relevant malfunction. The development and introduction of several RPh was facilitated by the R&D emphasis on addressing clinical needs, Particularly in the following areas: (i) for the skeletal system because the bone is a common site for cancer metastasis; (ii) for coronary imaging because it is a management tool for the huge number of cardiac patients and was first useful with 201TlCl before becoming more frequently used with 99mTc-based RPh (sestamibi, tetrofosmin); The following significant clinical achievements might be mentioned[1,2].

**Challenges**

Since quantitative imaging may often be used to quantify the biodistribution of the chemical, radionuclide treatment is more than merely radioactive chemotherapy. Furthermore, it is indirect. due to the geographical and temporal variability of the radiopharmaceutical's biodistribution, analogous to external beam treatment. A large influence is also played by dose-rate effects, DNA damage repair, and varied biology within a tumor. Since the radiopharmaceutical is frequently supplied systemically and ionizing radiation is the primary source of the therapy effect, the potential radiation risk associated with the treatment for patients is both deterministic (in target organs and lesions) and stochastic (in non-targeted tissue).As a result, there are a number of issues with radionuclide therapy that need to be resolved at the European level[4,5].

**Molecular imaging, SPECT imaging and PET scans, and radiotracers**

Nuclear Cardiology has had enormous progress over the past forty years due to an innovative and creative move away from subjective interpretations of The method is digitally based and uses mediocre radiotracers and quantitative planar images. For risk-stratifying patients for prospective intervention, medical care, or more intense intervention with coronary angiography and possibly revascularization, myocardial perfusion imaging has grown in importance. Planar imaging, which was quickly replaced by single photon emission tomography (SPECT), positron emission tomography, also called PET, and magnetic resonance imaging (MRI), has advanced at a rate comparable to that of the development and optimization of novel radiotracers that reflect the underlying molecular physiology of various cardiac disease states. These advancements include improved disease detection, diagnostic accuracy, and less exposure with no loss of picture quality[6-10].

**Production of radiopharmaceuticals**

Directives 2001/83/EC govern the production of radiopharmaceuticals used in clinical trials or as medical goods with marketing authorization in the EU[11]. 2001/20/EC[12] Specific EU and European Medicines Agency (EMA) guidelines further detail these criteria[13-15]. Examples are the Good Manufacturing Practice (GMP) rules in EudraLex Volume 4 and its annexes [16]. The introduction of GMP and its demanding standards for radiopharmaceuticals resulted in a considerable drop in clinical trials following the implementation of the aforementioned recommendations . In April 2014, Regulation EU 536/2014, which repeals Clinical trials for medications intended for human use are now governed under Directive 2001/20/EC[17].

**Radiopharmaceuticals' roles in nuclear medicine Classification, with the The "Value Matrix" Projections Option**

In a few particular circumstances, such as radioiodine treatment of metastatic (well-differentiated) thyroid cancer and high-resolution PET/CT imaging to precisely locate cancer metastasis (and plan the best course of action), such as metastasis of NET and prostate cancer (using 18F-FDG, 68Ga-ligand-vector conjugates), NM-RPh provides "unique value (indispensable role)". NM‑RPh provides "important value addition" in many other cases, e.g., myocardial imaging (perfusion using 99mTc items, 82Rb, 13NH3 , and sustainability utilizing 18F‑FDG), disease visualization (using 99mTc‑leucocytes, 99mTc‑UBI, 18F‑FDG, 68Ga‑UBI), supportive therapy for progressing osteoarthritis in people with cancer (using 89SrCl2 , 153Sm/177Lu‑EDTMP). The NMRPh for neurology's rapidly emerging developments will shortly add items to the list of "significant value additions," if not the list of "special values."[2].

**Particle-Emission Tomography/Computerized Tomography for Oncology Practice**

Due to the fact that 18F FDG PET/CT is now deeply ingrained into standard clinical oncology practice, it is crucial to comprehend both the important areas in which F-18 FDG PET/CT has a significant influence and the prospective areas in which further clinical expertise may be necessary. The most recent rules on the use of F-18 fluorescent dye PET/CT in tumor treatment[18].

**Conclusion**

A special technique known as nuclear medicine or molecular imaging (MI) offers functional pictures on inside organs. administration of tracer doses of radioisotopes. This specialty has advanced quickly during its more than 80-year career in medical science. improvements in radiochemistry, theragnostic, and combined imaging technology (PET/CT and SPECT/CT) The use of this modality has undergone a revolution in the management of the majority of solid tumors and other diseases as a result of the "treat what you see" and "see what you treat" philosophy. cancer of the blood, or hemo oncology. It is influencing the therapy of conditions in different therapeutic fields, including musculoskeletal disorders, infections and inflammations, pediatrics, endocrinology, neurology, and cardiology.

**REFERENCE**:-

1) Niese S. George de Hevesy (1885–1966): Founder of radioanalytical chemistry. Czech J Phys 2006;56 Suppl D:D3‑11.

2)Natesan Ramamoorthy1,2 1 Adjunct Faculty, National Institute of Advanced Studies (NIAS), IISc Campus, Bangaluru, Karnataka, India, 2 Division of Physical and Chemical Sciences, International Atomic Energy Agency (IAEA), Vienna, Austria.

3) Luster M, Clarke SE, Dietlein M, et al. Guidelines for radioiodine therapy of differentiated thyroid cancer. Eur J Nucl Med Mol Imaging. 2008;35:1941-1959

4)Michael Lassmann, Klinik und Poliklinik für Nuklearmedizin, Universitätsklinikum Würzburg, Oberdürrbacher Str. 6, D-97080 Würzburg, Germany. - 2228

6)M. J. Henzlova and W. L. Duvall, “The future of SPECT MPI: time and dose reduction,”The Journal of Nuclear Cardiology, vol. 18, no. 4, pp. 580–587, 2011.

5)Stokkel MP, Handkiewicz Junak D, Lassmann M, Dietlein M, Luster M. EANM procedure guidelines for therapy of benign thyroid disease. Eur J Nucl Med Mol Imaging. 2010;37:2218

[7] P. J. Slomka, D. Dey, W. L. Duvall, M. J. Henzlova, D. S. Berman, and G. Germano, “Advances in nuclear cardiac instrumentation with a view towards reduced radiation exposure,” Current Cardiology Reports, vol. 14, no. 2, pp. 208–216, 2012.

[8] G. R. Small, R. G. Wells, T. Schindler, B. J. W. Chow, and T. D. Ruddy, “Advances in cardiac SPECT and PET imaging: overcoming the challenges to reduce radiation exposure and improve accuracy,” Canadian Journal of Cardiology, vol. 29, no. 3, pp. 275–284, 2013.

[9] A. J. Einstein, K. W. Moser, R. C. Thompson, M. D. Cerqueira, and M. J. Henzlova, “Radiation dose to patients from cardiac diagnostic imaging,” Circulation, vol. 116, no. 11, pp. 1290–1305, 2007.

[10] S. Koshy and R. C. Thompson, “Review of radiation reduction strategies in clinical cardiovascular imaging,” Cardiology in Review, vol. 20, no. 3, pp. 139–144, 2012.

[11]. Langbein T, Weber WA, Eiber M (2019) Future of Theranostics: An Outlook on Precision Oncology in Nuclear Medicine, J Nucl Med 60:13S-19S doi: 10.2967/jnumed.118.220566

[12]. The European Parliament and the Council of the European Union. Directive 2001/83/EC of the European Parliament and of the Council of 6 November 2001 on the community code relating to medicinal products for human use. Off J Eur Communities. 2001

[13]. The European Parliament and the Council of the European Union. Directive 2001/20/EC of the European Parliament and of the Council of 4 April 2001 on the approximation of the laws, regulations and administrative provisions of the Member States relating to the implementation of good clinical practice in the conduct of clinical trials on medicinal products for human use. Off J Eur Communities. 2001

[14]. The European Parliament and the Council of the European Union. Directive 2003/94/EC of the European Parliament and of the Council of 8 October 2003 laying down the principles and guidelines of good manufacturing practice in respect of medicinal products for human use and investigational medicinal products for human use. Off J Eur Union. 2003

[15]. Lange R, ter Heine R, Decristoforo C et al. (2015), Untangling the web of European regulations for the preparation of unlicensed radiopharmaceuticals: a concise overview and practical guidance for a risk-based approach, J Nucl Med Comm 36(5):414-22. doi: 10.1097/MNM.0000000000000276.

[16]. European Commission. EudraLex The Rules Governing Medicinal Products in the European Union: EudraLex - Volume 4 - Good Manufacturing Practice (GMP) guidelines.

[17]. European Commission. Q&A: New rules for clinical trials conducted in the EU. 2014.

[18] Salaün PY, Abgral R, Malard O, Querellou‑Lefranc S, Quere G, Wartski M, et al. Good clinical practice recommendations for the use of PET/CT in oncology. Eur J Nucl Med Mol Imaging 2020;47:28‑50.